← Back to Search

Tyrosine Kinase Inhibitor

Treatment for Neuroendocrine Tumors

N/A
Waitlist Available
Research Sponsored by Hutchison Medipharma Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Hutchison Medipharma LimitedLead Sponsor
101 Previous Clinical Trials
13,609 Total Patients Enrolled
6 Trials studying Neuroendocrine Tumors
744 Patients Enrolled for Neuroendocrine Tumors
HutchmedLead Sponsor
32 Previous Clinical Trials
6,322 Total Patients Enrolled
3 Trials studying Neuroendocrine Tumors
249 Patients Enrolled for Neuroendocrine Tumors
John Kauh, MDStudy ChairHutchison Medipharma Limited
7 Previous Clinical Trials
452 Total Patients Enrolled
3 Trials studying Neuroendocrine Tumors
249 Patients Enrolled for Neuroendocrine Tumors
~233 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top